science
plus
.abes.fr
|
explorer
À propos de :
Antman Elliott M
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
foaf:Person
, within Data Space :
scienceplus.abes.fr
associated with source
document(s)
Type:
Person
New Facet based on Instances of this Class
Attributs
Valeurs
type
Person
degree
MD, FACC, FAHA
name
Antman Elliott M
Antman Elliott M.
Antman Elliott
personal mailbox
eantman@partners.org
eantman@rics.bwh.harvard.edu
familyName
Antman
Given name
Elliott
Elliott M.
Elliott M
is
relates
of
http://hub.abes.fr/oup/periodical/eurheartj/2006/volume_27/issue_16/101093eurheartjehl176/authorship/37
http://hub.abes.fr/oup/periodical/ehjsupp/2004/volume_6/issue_supplb/101016jehjsup200401012/authorship/1
http://hub.abes.fr/oup/periodical/eurheartj/2009/volume_30/issue_14/101093eurheartjehp159/authorship/12
http://hub.abes.fr/oup/periodical/ehj/2007/volume_28/issue_13/101093eurheartjehm179/authorship/11
http://hub.abes.fr/oup/periodical/eurheartj/2004/volume_25/issue_22/101016jehj200408016/authorship/9
http://hub.abes.fr/bmj/periodical/bmj/2010/volume_340/issue_2010/B36ED9CE695A0C0CE053120B220A1E16/authorship/2
http://hub.abes.fr/oup/periodical/ehjsupp/2004/volume_6/issue_supplb/101016jehjsup200401011/authorship/2
http://hub.abes.fr/oup/periodical/eurheartj/2003/volume_24/issue_20/101016jehj200308002/authorship/17
http://hub.abes.fr/oup/periodical/eurheartj/2004/volume_25/issue_13/101016jehj200404036/authorship/2
http://hub.abes.fr/oup/periodical/eurheartj/2006/volume_27/issue_7/101093eurheartjehi775/authorship/2
http://hub.abes.fr/oup/periodical/eurheartj/2007/volume_28/issue_20/101093eurheartjehm355/authorship/33
http://hub.abes.fr/oup/periodical/eurheartj/2008/volume_29/issue_20/101093eurheartjehn362/authorship/2
http://hub.abes.fr/oup/periodical/ehj/2007/volume_28/issue_9/101093eurheartjehm016/authorship/7
http://hub.abes.fr/oup/periodical/eurheartj/2007/volume_28/issue_17/101093eurheartjehm210/authorship/10
http://hub.abes.fr/oup/periodical/eurheartj/2010/volume_31/issue_17/101093eurheartjehq100/authorship/4
http://hub.abes.fr/oup/periodical/eurheartj/2005/volume_26/issue_7/101093eurheartjehi094/authorship/6
http://hub.abes.fr/oup/periodical/eurheartj/2010/volume_31/issue_17/101093eurheartjehq098/authorship/2
http://hub.abes.fr/oup/periodical/eurheartj/2004/volume_25/issue_19/101016jehj200405009/authorship/3
http://hub.abes.fr/oup/periodical/eurheartj/2004/volume_25/issue_12/101016jehj200404029/authorship/3
http://hub.abes.fr/oup/periodical/ehj/2007/volume_28/issue_9/101093eurheartjehm081/authorship/7
http://hub.abes.fr/oup/periodical/eurheartj/2007/volume_28/issue_17/101093eurheartjehm224/authorship/10
http://hub.abes.fr/oup/periodical/eurheartj/2007/volume_28/issue_23/101093eurheartjehm471/authorship/2
http://hub.abes.fr/oup/periodical/ehj/2006/volume_27/issue_17/101093eurheartjehl199/authorship/37
http://hub.abes.fr/oup/periodical/eurheartj/2005/volume_26/issue_5/101093eurheartjehi104/authorship/5
http://hub.abes.fr/springer/periodical/11239/1994/volume_1/issue_1/B8FE58E661901F79E053120B220A405E/authorship/2
http://hub.abes.fr/springer/periodical/10557/1996/volume_10/issue_3/B912FEC314163DF8E053120B220A8451/authorship/1
is
Author
of
ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—executive summary
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis
Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis
Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome
Selection of the optimal reperfusion strategy for STEMI: does time matter? The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
Introduction
Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25
Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial
The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
Universal definition of myocardial infarction
Time is muscle in primary PCI: the strength of the evidence grows
One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 Trial
A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary
Enoxaparin and ST-elevation myocardial infarction: reply
Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death—executive summary
Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction
Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial
The re-emergence of anticoagulation in coronary disease
Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials
Time as an adjunctive agent to thrombolytic therapy
Magnesium in acute myocardial infarction: Scientific, statistical, and economic rationale for its use
Alternative Linked Data Documents:
ODE
Content Formats:
RDF
ODATA
Microdata
